Top Markets
Coin of the day
Graphite Bio, Inc. Graphite Bio, Inc.

Graphite Bio, Inc.

GRPH
Rankning i aktier #12751
Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to... Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to developing innovative therapeutic solutions for severe and life-threatening illnesses across the United States. Its primary investigational therapy, GPH101, is an autologous, gene-edited hematopoietic stem cell product specifically engineered to directly correct the underlying mutation causing sickle cell disease, thereby restoring normal adult hemoglobin production. The company's pipeline also features GPH201, intended for the treatment of X-linked severe combined immunodeficiency syndrome, and GPH301, an experimental candidate designed to address Gaucher disease, a genetic disorder characterized by a deficiency in the glucocerebrosidase enzyme. Initially established as Integral Medicines, Inc., the company rebranded to Graphite Bio, Inc. in August 2020. Founded in 2017, Graphite Bio's operations are based out of its headquarters in South San Francisco, California.
Aktiekurs
$22.26
Senast synkroniserad: 2024-03-22
Marknadsvärde
$553.40M
Förändring (1 dag)
0.00%
Förändring (1 år)
0.00%
Land
US
Handel Graphite Bio, Inc. (GRPH)

Kategori

Utdelningsavkastning för Graphite Bio, Inc. (GRPH)
Utdelningsavkastningen (TTM) för Graphite Bio, Inc. (aktiesymbol: GRPH) per 2026 är: 0
Genomsnittlig utdelningsavkastning de senaste 5 åren: 0.00%
Historik för utdelningsavkastning för Graphite Bio, Inc. (GRPH) från 2026 till 2026
Utdelningsavkastning i slutet av varje år (TTM)
År Utdelningsavkastning Ändra
Inte tillräckligt med data för de angivna datumen.
Utdelningsavkastning (TTM) för liknande företag eller konkurrenter
Företag Utdelningsavkastning Land
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH